Stephen L. Chia

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 16, 2026

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

Journal: Cancer treatment reviews

Published: April 28, 2026

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 24, 2026

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 16, 2026

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Journal: Breast (Edinburgh, Scotland)

Published: April 08, 2026

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

Journal: NPJ breast cancer

Published: March 09, 2026

Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).

Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).

Journal: Journal of the National Cancer Institute

Published: February 06, 2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Journal: Current oncology (Toronto, Ont.)

Published: January 28, 2026

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 25, 2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Journal: Current oncology (Toronto, Ont.)

Published: January 16, 2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.

Journal: Current oncology (Toronto, Ont.)

Published: December 24, 2025

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

Journal: Current oncology (Toronto, Ont.)

Published: December 07, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026